Level Four Advisory Services LLC Grows Stake in Inari Medical, Inc. (NASDAQ:NARI)

Level Four Advisory Services LLC boosted its stake in Inari Medical, Inc. (NASDAQ:NARI) by 28.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,164 shares of the company’s stock after buying an additional 933 shares during the quarter. Level Four Advisory Services LLC’s holdings in Inari Medical were worth $270,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its holdings in shares of Inari Medical by 7.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock valued at $38,693,000 after acquiring an additional 41,555 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Inari Medical by 23.4% in the 4th quarter. Principal Financial Group Inc. now owns 567,266 shares of the company’s stock valued at $36,827,000 after purchasing an additional 107,622 shares in the last quarter. Fiera Capital Corp boosted its stake in Inari Medical by 63.4% during the 3rd quarter. Fiera Capital Corp now owns 560,756 shares of the company’s stock worth $36,673,000 after purchasing an additional 217,606 shares during the last quarter. Bamco Inc. NY grew its holdings in shares of Inari Medical by 18.2% during the third quarter. Bamco Inc. NY now owns 557,937 shares of the company’s stock worth $36,489,000 after buying an additional 86,000 shares in the last quarter. Finally, Fred Alger Management LLC raised its position in shares of Inari Medical by 10.4% in the third quarter. Fred Alger Management LLC now owns 499,989 shares of the company’s stock valued at $32,699,000 after buying an additional 47,251 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Stock Performance

NASDAQ:NARI opened at $47.67 on Thursday. The stock’s 50 day moving average price is $42.71 and its 200 day moving average price is $52.59. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $71.85.

Inari Medical (NASDAQ:NARI) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.15). The firm had revenue of $143.19 million during the quarter, compared to analysts’ expectations of $138.32 million. Inari Medical had a negative net margin of 4.54% and a negative return on equity of 1.65%. As a group, equities research analysts predict that Inari Medical, Inc. will post -0.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Piper Sandler lowered their price target on shares of Inari Medical from $55.00 to $50.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. Truist Financial dropped their price target on Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research report on Friday, March 22nd. Canaccord Genuity Group lowered their price objective on Inari Medical from $75.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Needham & Company LLC reduced their price target on Inari Medical from $72.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Finally, Wells Fargo & Company lowered their price target on shares of Inari Medical from $100.00 to $84.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $65.71.

Insider Transactions at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $41.13, for a total value of $1,645,200.00. Following the completion of the sale, the director now owns 1,003,296 shares in the company, valued at $41,265,564.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Inari Medical news, Director Rebecca Chambers sold 964 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $45.39, for a total value of $43,755.96. Following the completion of the transaction, the director now owns 9,944 shares in the company, valued at $451,358.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $41.13, for a total value of $1,645,200.00. Following the completion of the sale, the director now directly owns 1,003,296 shares of the company’s stock, valued at approximately $41,265,564.48. The disclosure for this sale can be found here. Insiders have sold a total of 132,964 shares of company stock worth $5,751,634 over the last ninety days. 10.60% of the stock is currently owned by company insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.